Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, VANDA PHARMACEUTICALS INC. reported revenue of $216M, up 8.7% year over year. Operating margin was -70.0% and net margin -102.0%, on a free-cash-flow margin of -51.1% with capital expenditure at 0.5% of revenue. Every figure is computed directly from VNDA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $216M | -70.0% | -102.0% |
| FY2024 | $199M | -20.5% | -9.5% |
| FY2023 | $193M | -7.2% | 1.3% |
| FY2022 | $254M | 2.5% | 2.5% |
| FY2021 | $269M | 15.7% | 12.3% |
How does VNDA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.